CLRB News and Press, Cellectar Biosciences Inc. From 05/10/22

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results ...

Cellectar Biosciences (NASDAQ:CLRB) on Tuesday said an independent committee recommended that the company continue its phase 2b study of its cancer therapy iopofosine to treat Waldenstrom’s macroglobulinemia (WM), a rare type of cancer that begins in the white blood cells. CLRB said an...

FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced an independent D...

Matthew Hagan Appointed Vice President, Marketing and Strategic Alliances David Lasecki Appointed Executive Director, Strategic Alliances FLORHAM PARK, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharma...

Cellectar Biosciences Inc. (NASDAQ:CLRB) traded today at a new 52-week high of $14.46. This new high was reached on above average trading volume as 106.2 million shares traded hands, while the average 30-day volume is approximately 173,000 shares. In the past 52 weeks, Cellectar Bioscien...

Cellectar Biosciences press release (NASDAQ:CLRB): FY GAAP EPS of -$0.43 beats by $0.01. As of December 31, 2021, the company had cash and cash equivalents of $35.7 million, compared to $57.2 million at December 31, 2020. For further details see: Cellectar Biosciences GAAP EPS...

FLORHAM PARK, N.J., March 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial result...

FLORHAM PARK, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced the company will partici...

Cellectar Biosciences (NASDAQ:CLRB) names Mr. Chad Kolean as Chief Financial Officer and promoted Mr. Jarrod Longcor to the role of Chief Operating Officer.  Mr. Kolean, a seasoned thirty-year industry veteran, will replace Dov Elefant, who is leaving to pursue o...

Names Mr. Chad Kolean as Chief Financial Officer Promotes Mr. Jarrod Longcor to Chief Operating Officer FLORHAM PARK, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the dis...